Melfalan Tillomed (Melphalan)

Melphalan belongs to the alkylating agent class. It binds to DNA, forming cross‑links that prevent DNA replication and transcription. This damage triggers programmed cell death (apoptosis) in cancer cells that are actively dividing.

The specific dose of Melfalan Tillomed is determined by the prescribing oncologist based on the patient’s diagnosis, body surface area, renal function and treatment protocol. The prescriber sets the exact amount and schedule for each individual.

Melphalan is classified as contraindicated in pregnancy because it can cause fetal harm. It is also not recommended during breastfeeding, as it may be excreted in milk and affect the infant. Patients should discuss contraception and lactation plans with their healthcare provider.

To request Melfalan Tillomed, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Melphalan is an alkylating agent, differing from antimetabolites or taxanes in its mechanism of forming DNA cross‑links. Compared with other alkylators, melphalan has a well‑established role in multiple myeloma and certain solid tumours, but its toxicity profile, especially myelosuppression, may be more pronounced than some newer targeted therapies.

Melfalan Tillomed should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. Follow any additional handling instructions provided with the product.

Melfalan Tillomed is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are determined by the treatment protocol and patient tolerance, and the drug is typically diluted in a compatible IV solution before administration.

Serious risks include severe bone‑marrow suppression leading to infection or bleeding, secondary malignancies such as therapy‑related leukemia, pulmonary toxicity, renal impairment and rare anaphylactic reactions. Patients should be monitored closely for signs of infection, respiratory distress, renal dysfunction and any allergic symptoms.

Melfalan Tillomed should not be used in patients with known hypersensitivity to melphalan or other alkylating agents, in pregnant women, or in individuals with severe uncontrolled infections. Caution is also advised for patients with significant renal or hepatic impairment, and those receiving live vaccines.